Parkure Ltd will use any appropriate way to develop a cure for Parkinson’s disease.
Our current lead technology makes use of drug testing procedures using fruit flies. There is a lot of high quality evidence from academic science to show that the fruit fly Drosophila melanogaster develops symptoms of Parkinson’s disease when challenged by the expression of certain human proteins – known to cause Parkinson’s disease in man – in its brain. The molecular mechanisms by which nerve cells act and communicate are remarkably similar in flies and man. Some of the genes that cause hereditary Parkinson’s disease in man were actually discovered in the fruit fly, where they act in an identical fashion. Discoveries made in the fruit fly will in almost all cases be adaptable to the human system.
Parkure has refined the use of fruit flies as an platform for drug screening against Parkinson’s disease. The primary screening assay is fast and cheap enough to allow a large number of chemicals to be tested, increasing the probability of success. The assay is scaleable to very large numbers of chemicals. The platform is completed by a follow-up process that can allow the effective prioritisation of lead candidates so they call be finally be pre-clinically tested.
The platform has been put to the test commercially and has already delivered strong results. A recent collaboration with leading US researchers and a pharmaceutical company led to strong evidence of Parkure’s platform forward translation potential, with a drug (non-marketed, repurposed) showing effects in two mouse models of Parkinson’s disease.
We focus on screening carefully selected novel compounds but also repurposing drugs. Parkure’s pipeline includes drugs from both categories, two of which have been pre-clinically validated and are now being further developed.